Moderna’s vaccine for the treatment of COVID-19 has received full approval from the US Food and Drug Administration for people 18 years of age or older, an important step that promotes the use of the vaccine as a major weapon in the war against Corona.
The vaccine, called Spikevax, was used in US adults under an emergency use authorization from the Food and Drug Administration, but the full clearance allows Moderna to market the vaccine to adults with full FDA approval.
Moderna’s stock jumped 2.8% to $163.93. The company had applied for approval last June.
It is worth noting that Pfizer has the only other fully authorized vaccine in the United States, which was approved by the Food and Drug Administration in August.
Related posts:
European Central Bank Governor François Villeroy de Galhau on the Risks and Future of Monetary ...
USA: Shortage of baby milk: Abbott CEO apologizes
Amazon wants to double its investments in brick-and-mortar commerce
Central bank rate hikes exacerbate the risk of a global recession
Climate: rich countries must get out of fossil fuels first
The price of Japanese 1-inch CMOS flagship mobile phone dropped to 6,000! What price will netizens b...
After the election, stocks return to fundamentals, pay attention to the impact of foreign exchange l...
The Dow closed down 4.81 points after Powell reiterated his move forward. : InfoQuest